WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2016 financial results on Thursday, February 23, 2017.
In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, February 23, 2017 to discuss the results and provide a company update.
Conference Call Information:
Date: Thursday, February 23, 2017
Time: 4:30 p.m. ET
Domestic Dial-in Number: 1-877-705-6003
International Dial-in Number: 1-201-493-6725
Live webcast: http://public.viavid.com/index.php?id=122846
For those unable to participate in the conference call or webcast, a replay will be available beginning February 23, 2017 at 7:00 p.m. ET until March 9, 2017 at 11:59 p.m. ET. To access the replay, dial 1-844-512-2921 for U.S. or 1-412-317-6671 for International. The replay pin number is 13654552.
A live audio webcast of the call can be accessed from the Investors section of the Company's website, www.radiuspharm.com, where a webcast replay will be also available for 14 days. The full text of the announcement and financial results will also be available on the Company's website.
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the treatment of postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review by the EMA in Europe and a New Drug Application (NDA) has been accepted for filing by the FDA with a PDUFA date of March 30, 2017. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in postmenopausal women with osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in cancer. For more information, please visit www.radiuspharm.com
Source:Radius Health Inc.